Tricida to Report First Quarter Financial Results and Host Conference Call and Webcast on Thursday, May 6, 2021

Rhea-AI Summary

Tricida, Inc. (Nasdaq: TCDA) will report its Q1 2021 financial results on May 6, 2021, at 4:30 PM ET. Following the results, a conference call and webcast will provide insights into the company's progress. Tricida focuses on developing the oral drug veverimer to treat metabolic acidosis in chronic kidney disease (CKD) patients, a condition affecting an estimated three million individuals in the U.S. The company emphasizes its commitment to addressing significant health risks associated with CKD.

Positive

• Tricida's investigational drug veverimer targets metabolic acidosis in CKD, addressing a significant health issue for three million patients in the U.S.

Negative

• None.

SOUTH SAN FRANCISCO, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will report its first quarter 2021 financial results after the close of market on Thursday, May 6, 2021. Tricida will host a conference call and webcast at 4:30 pm Eastern Time to discuss its first quarter financial results and business progress. The call or webcast may be accessed as follows:

Tricida Conference Call Information

Tricida will host its First Quarter Financial Results and Business Update Conference Call and webcast on Thursday, May 6, 2021 at 4:30 pm Eastern Time. The call or webcast may be accessed as follows:

Tricida Conference Call Thursday, May 6, 2021 4:30 pm Eastern Time
	Webcast: Dial-In: International: Conference ID:	IR.Tricida.com (877) 377-5478 (629) 228-0740 9047649

A replay of the webcast will be available on Tricida’s website approximately two hours following the completion of the call and will be available for up to 90 days following the presentation.

About Tricida

Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. It is estimated to pose a health risk to approximately three million patients with CKD in the United States.

For more information about Tricida, please visit www.Tricida.com.

Contact:
Jackie Cossmon
Tricida, Inc.
Senior Vice President of Investor Relations and Communications
IR@Tricida.com

Source: Tricida, Inc.

FAQ

When will Tricida report its Q1 2021 financial results?

Tricida will report its Q1 2021 financial results on May 6, 2021, after market close.

What is the purpose of Tricida's conference call on May 6, 2021?

The conference call on May 6, 2021, is to discuss Tricida's first quarter financial results and business progress.

How does veverimer aim to help patients with chronic kidney disease?

Veverimer is designed to treat metabolic acidosis, a condition that can worsen chronic kidney disease and affect millions.